These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 36776840)

  • 41. Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future Directions.
    Bhalla S; Doroshow DB; Hirsch FR
    Cancer J; 2020; 26(6):507-516. PubMed ID: 33298722
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immune Oncology Biomarkers in Lung Cancer: an Overview.
    Travert C; Barlesi F; Greillier L; Tomasini P
    Curr Oncol Rep; 2020 Aug; 22(11):107. PubMed ID: 32803433
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma.
    Jang SR; Nikita N; Banks J; Keith SW; Johnson JM; Wilson M; Lu-Yao G
    JAMA Netw Open; 2021 Dec; 4(12):e2136823. PubMed ID: 34854905
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Clinical analysis of combined immunotherapy in patients with malignant pleural mesothelioma].
    Zhao C; Fei KL; Wan R; Song LP; Xiang PC; Duan JC
    Zhonghua Zhong Liu Za Zhi; 2023 May; 45(5):445-451. PubMed ID: 37188631
    [No Abstract]   [Full Text] [Related]  

  • 45. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Evolving Role of Immune-Checkpoint Inhibitors in Malignant Pleural Mesothelioma.
    Borgeaud M; Kim F; Friedlaender A; Lococo F; Addeo A; Minervini F
    J Clin Med; 2023 Feb; 12(5):. PubMed ID: 36902544
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1.
    Lefler DS; Snook AE; Bashir B
    Immunotherapy; 2022 Aug; 14(11):885-902. PubMed ID: 35694998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
    Dai C; Liang S; Sun B; Kang J
    Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
    Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
    J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
    Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunotherapy and predictive immunologic profile: the tip of the iceberg.
    Cunha Pereira T; Rodrigues-Santos P; Almeida JS; Rêgo Salgueiro F; Monteiro AR; Macedo F; Soares RF; Domingues I; Jacinto P; Sousa G
    Med Oncol; 2021 Mar; 38(5):51. PubMed ID: 33788049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meta-Analysis on the Combination of Chemotherapy With Programmed Death-Ligand 1 and Programmed Cell Death Protein 1 Blockade as First-Line Treatment for Unresectable Pleural Mesothelioma.
    Tagliamento M; Di Maio M; Remon J; Bironzo P; Genova C; Facchinetti F; Aldea M; Le Péchoux C; Novello S; Barlesi F; Besse B; Planchard D
    J Thorac Oncol; 2024 Jan; 19(1):166-172. PubMed ID: 37567387
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Mechanisms of resistance to immune checkpoint inhibitors in melanoma: What we have to overcome?
    Ziogas DC; Theocharopoulos C; Koutouratsas T; Haanen J; Gogas H
    Cancer Treat Rev; 2023 Feb; 113():102499. PubMed ID: 36542945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High-intensity statins are associated with improved clinical activity of PD-1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients.
    Cantini L; Pecci F; Hurkmans DP; Belderbos RA; Lanese A; Copparoni C; Aerts S; Cornelissen R; Dumoulin DW; Fiordoliva I; Rinaldi S; Aerts JGJV; Berardi R
    Eur J Cancer; 2021 Feb; 144():41-48. PubMed ID: 33326868
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunotherapy-related biomarkers: Confirmations and uncertainties.
    Catalano M; Iannone LF; Nesi G; Nobili S; Mini E; Roviello G
    Crit Rev Oncol Hematol; 2023 Dec; 192():104135. PubMed ID: 37717881
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
    Quispel-Janssen J; van der Noort V; de Vries JF; Zimmerman M; Lalezari F; Thunnissen E; Monkhorst K; Schouten R; Schunselaar L; Disselhorst M; Klomp H; Hartemink K; Burgers S; Buikhuisen W; Baas P
    J Thorac Oncol; 2018 Oct; 13(10):1569-1576. PubMed ID: 29908324
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy.
    Desai AP; Kosari F; Disselhorst M; Yin J; Agahi A; Peikert T; Udell J; Johnson SH; Smadbeck J; Murphy S; Karagouga G; McCune A; Schaefer-Klein J; Borad MJ; Cheville J; Vasmatzis G; Baas P; Mansfield A
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37279993
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers.
    Giorgione R; Risaliti M; Bartolini I; Rossi G; Pillozzi S; Muiesan P; Taddei A; Antonuzzo L
    Immunotherapy; 2022 May; 14(7):567-576. PubMed ID: 35382560
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potential Predictive and Prognostic Value of Biomarkers Related to Immune Checkpoint Inhibitor Therapy of Triple-Negative Breast Cancer.
    Tan Q; Yin S; Zhou D; Chi Y; Man X; Li H
    Front Oncol; 2022; 12():779786. PubMed ID: 35646659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.